[en] Sumatriptan is a potent and selective agonist at the vascular 5HT1 receptor which mediates constriction of certain large cranial blood vessels and/or inhibits the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater following activation of the trigeminovascular system. The mode of action of this drug in migraine and cluster headache is discussed. On the basis of a detailed review of all published trials and available data from post-marketing studies, the efficacy, safety, tolerability and the place of oral and subcutaneous sumatriptan in the treatment of both conditions are assessed. A number of double-blind clinical trials have demonstrated that sumatriptan 100 mg administered orally is clearly superior to placebo in the acute treatment of migraine headache and achieves significantly greater response rates than ergotamine or aspirin. In other studies, 70 to 80% of patients receiving sumatriptan 6 mg sc experienced relief of migraine headaches by 1 or 2 h after administration, and patients consistently required less rescue medication for unresolved symptoms. Sumatriptan was also effective in relieving associated migraine symptoms like nausea and vomiting. Sumatriptan was equally effective regardless of migraine type or duration of migraine symptoms. Overall, approximately 40% of patients who initially responded to oral or subcutaneous sumatriptan experienced recurrence of their headache usually within 24 h, effectively treated by a further dose of this drug. In 75% of patients with cluster headache treated with sumatriptan 6 mg sc, relief was achieved within 15 min. Based on pooled study data, sumatriptan is generally well tolerated and most adverse events are transient. Adverse events following oral administration include nausea, vomiting, malaise, fatigue and dizziness. With the subcutaneous injection, injection site reactions occur in approximately 30%. Chest syumptoms are reported in 3 to 5% but have been associated with myocardial ischaemia only in rare isolated cases. The recommended dosage of sumatriptan at the onset of migraine symptoms is 100 mg orally or 6 mg subcutaneously. The recommended dosage for cluster headache is 6 mg sumatriptan sc. Sumatriptan must not be given together with vasoconstrictive substances, e.g., ergotamines, or with migraine prophylactics with similar properties, e.g., methysergide. Sumatriptan should not be given during the migraine aura. It is contraindicated in patients with ischaemic heart disease, previous myocardial infarction, Prinzmetal (variant) angina and uncontrolled hypertension.
Disciplines :
Neurology Neurosciences & behavior
Author, co-author :
Wilkinson, M.
Pfaffenrath, V.
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Diener, H. C.
Steiner, T. J.
Language :
English
Title :
Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience.
Publication date :
1995
Journal title :
Cephalalgia
ISSN :
0333-1024
eISSN :
1468-2982
Publisher :
Blackwell Science, Osney Mead Oxford, United Kingdom
Wilkinson M Treatment of the acute migraine attack-current status. Cephalalgia 1982; 3: 61-67
Olesen J A review of current drugs for migraine. J Neurol 1991; 238 Suppl 1: S23-S27
Diener HC Limmroth V The treatment of migraine. Rev Contemp Pharmacother 1994; 5: 271-284.
Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl 7: 1-96
Olesen J Friberg L Olsen TS Iversen HK Lassen NA Andersen AR, et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990; 28: 791-798.
Olsen TS Friberg L Larsen NA Ischaemia may be the primary cause of the neurologic deficits in classic migraine. Arch Neurol 1987; 44: 156-161.
Bès A Fabre N Soulages X Pavy-Le-Traon A Geraud G La migraine est-elle une maladie vasculaire? Circulation et Métabolisme du Cerveau 1990; 7: 251-266.
Barkley GL Tepley N Simkins R Moran J Welch KMA Neuromagnetic fields in migraine: preliminary findings. Cephalalgia 1990; 10: 171-176.
Schoenen J Jamart B Delwaide PJ Topographic EEG mapping in common and classic migraine during and between attacks. In: Clifford Rose F, editor.Advances in Headache Research. London: John Libbey 1987: 25-33
Welch KM Levine SR D'Andrea G Schultz L Helpern JA Preliminary observations on brain energy metabolism in migraine studied by in vivo 31-phosphorus NMR spectroscopy. Neurology 1989; 39: 538-541.
Thie A Fuhlendorf A Spitzer K Kunze K Transcranial Doppler evaluation of common and classic migraine. Part II. Ultrasonic features during attacks. Headache 1990; 30: 209-215.
Friberg L Olsen J Iversen HK Sperling B Migraine pain associated with middle cerebral artery dilatation; reversal by sumatriptan. Lancet 1991; 338: 13-17
Caekebeke JFV Ferrari MD Zwetsloot CP Jansen J Saxena PR Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology 1992; 42: 1522-1526.
Caekebeke JFV Saxena PR Ferrari MD Effect of sumatriptan on cranial blood flow velocity during and between migraine attacks. In: Olesen J Saxena PR, editors.Frontiers in Headache Research: 5-Hydroxytryptamine mechanisms in primary headaches. New York: Raven Press, 1992: 273-277.
Zweetsloot CP Caekebeke JFV Ferrari MD Lack of asymmetry of middle cerebral artery blood velocity in unilateral migraine. Stroke 1993; 24: 1335-1338.
Visser WH Does a combined regimen of subcutaneous followed by oral sumatriptan prevent headache recurrence. Cephalalgia 1993; 13 Suppl 13: 189
Goadsby PJ Edvinsson L Ekman R Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183-187.
Goadsby PJ Edvinsson L The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48-56
Anthony M Lance JW Serotonin in migraine. In: Pearce JMS, editor.Topics in Migraine. London: Heinemann, 1975
Ferrari MD Odink J Tapparelli C Van Kempen GMJ Pennings EMJ Bruyn GW Serotonin metabolism in migraine. Neurology 1989; 39: 1239-1242.
Woods RP Iacoboni M Mazziotta JC Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994; 331: 1689-1692.
Moskowitz MA The visceral organ brain: implications for the pathophysiology of vascular head pain. Neurology 1991; 41: 182-186.
Moskowitz MA Cutrer FM Sumatriptan: a receptor-targeted treatment of migraine. Ann Rev Med 1993; 44: 145-154.
Wei EP Moskowitz MA Boccalini P Kontos HA Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles. Circ Res 1992; 70: 1313-1319.
Nichols FT Mawad M Mohr JP Stein B Hilal S, et al. Focal headache during balloon inflation in the internal carotid and middle cerebral arteries. Stroke 1990; 21: 555-559.
Ray BS Wolff HG Experimental studies on headache: pain-sensitive structures of the head and their significance in headache. Arch Surg 1940; 41: 813-856.
Diener C Limmroth V May A Laurich F Auerbach P Wosnitza G, et al. Changes of cerebral blood flow velocity after treatment of migraine with sumatriptan or placebo. Cephalalgia 1993; 13 Suppl 13: 14
Ferrari MD Saxena PR On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 1993; 13: 151-165.
Ferrari MD Biochemistry of migraine. Pathol Biol 1992; 40: 287-292.
Edmeads J Migraine-disease or syndrome? Pathol Biol 1992; 40: 279-283.
Moskowitz MA Neurovascular mechanisms in the pathogenesis and treatment of migraine. Abstracts 7th World Congress on Pain. IASP Publications. Seattle, 1993: 253
Olesen J Cerebral blood flow in migraine with aura. Pathol Biol 1992; 40: 318-324.
Olsen TS Spreading oligaemia in the migraine aura- most likely an artifact due to scattered radiation. Cephalalgia 1993; 13: 86-88
Sjaastad O Cluster headache syndrome. Major problems in neurology. London: WB Saunders, 1992
Hannerz J Greitz D MRI of intracranial arteries in nitroglycerin induced cluster headache attacks. Headache 1992; 32: 485-488.
Nappi G Savoldi F Headache: diagnostic system and taxonomic criteria. London: John Libbey, 1985
Moskowitz MA Cluster headache: evidence for a patho-physiological focus in the superior pericarotid cavernous sinus plexus. Headache 1988; 28: 584-586.
Humphrey PPA Apperley E Feniuk W Perren MJ A rational approach to identifying a fundamentally new drug for the treatment of migraine. In: Saxena PR Wallis DI Wouters W Bevan P, editors.Cardiovascular pharmacology of 5-hydroxytryptamine. Dordrecht: Kluwer, 1990: 417-431.
Connor HE Feniuk W Lloyd K Humphrey PPA Migraine, serotonin and sumatriptan. Vasc Med Rev 1992; 3: 95-108
Saxena PR Ferrari MD 5-HT1-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 1989; 10: 200-204.
Humphreys PPA 5-Hydroxytryptamine receptors: classification, molecular structure, and transduction mechanisms. In: Olesen J Saxena PR, editors.5-Hydroxytryptamine mechanisms in primary headache. New York: Raven Press, 1992: 109-117.
Humphrey PPA Hartig P Hoyer D A proposed new nomenclature for 5-HT-receptors. Trends Pharmacol Sci 1993; 14: 233-236.
Buzzi MG Carter WB Shimizu T Heath H III Moskowitz MA Dihydroergotamine and sumatriptan attenuate the increase in plasma calcitonin gene-related peptide levels within rat superior sagittal sinus during electrical trigeminal ganglion stimulation. Neuropharmacology 1991; 30: 1193-200
Humphrey PPA Feniuk W Perren MJ Connor HE Oxford AW Coates IH, et al. GR43175, a selective agonist for 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol 1988; 94: 1123-1132.
Humphrey PPA Feniuk W Marriott AS Tanner RJN Jackson MR Tuchner ML Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol 1991: 281-290.
Vincent MB White LR Bakken IJ Sjaastad O Sumatriptan relaxes isolated porcine ophthalmic artery, but inhibits VIP-induced relaxation. Cephalalgia 1993; 13: 378-382.
Bax WA Van Heuven-Nolsen D Tadipatri S Bos E Simoons ML Saxena PR Sumatriptan contracts human isolated saphenous vein via a 5-HT1-like receptor resembling to 5-HT1D receptor subtype. In: Olesen I Saxena PR, editors.5-Hydroxytryptamine mechanisms in primary headaches. New York: Raven Press, 1992: 178-182.
Lloyd DK Arnold WSG Long-term use of sumatriptan. Br Med J 1994; 308: 553
Chester AH Martin GR Bodelsson M Ameko-Noboin B Tadjkarimi S, et al, 5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries. Cardiovasc Res 1990; 24: 932-937.
Connor HE Feniuk W Humphrey PPA 5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. Eur J Pharmacol 1989; 161: 91-94
Panconesi A Franchi G Anselmi B Curradi C Tarquini B Amplifying effect of sumatriptan on noradrenaline venoconstriction in migraine patients. Cephalalgia 1993; 13: 383-388.
Connor HE Feniuk W Humphrey PPA Characterization of 5-HT receptors mediating contraction of canine and primate basilar artery by use of GR43175, a selective 5-HT1-like receptor agonist. Br J Pharmacol 1989; 96: 379-387.
Connor HE O'Shaughnessy CT Effects of sumatriptan on sensory neurotransmission in guinea-pig basilar arteries. Cephalalgia 1993; 13 Suppl 13: 42
Feniuk W Humphrey PPA Perren MJ The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. Br J Pharmacol 1989; 96: 83-90
Perren MJ Feniuk W Humphrey PPA The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia 1989; 9 Suppl 9: 41-46
Den Boer MO Villalon CM Heiligers JPC Humphrey PAA Saxena PR Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol 1991; 102: 323-330.
Sleight AJ Cervenka A Peroutka SJ In vivo effects of sumatriptan (GR43175) on extracellular levels of 5-HT in the guinea pig. Neuropharmacology 1990; 29: 551
Hamel E Bouchard D Contractile 5-HT1 receptors in human isolated pial arterioles: correlation with 5-HT1D binding sites. Br J Pharmacol 1991; 102: 227-233.
Jansen J Edvinsson L Mortensen A Olesen J Sumatriptan is a potent vasoconstrictor of human dural arteries. Cephalalgia 1992; 12: 202-205.
Diener HC Peters C Rudzio M Noe A Dichgans J Haux R, et al. Ergotamine, flunarizine and sumatriptan do not change cerebral blood flow velocity in normal subjects and migraineurs. J Neurol 1991; 238: 245-250.
Fabre N Gu X Pavy A Geraud G Bes A Effect of sumatriptan on flow velocities in middle cerebral arteries during migraine attacks without aura. Cephalalgia 1993; 13 Suppl 13: 15
Nozaki K Moskowitz MA Boccalini P CP-93, 129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992; 106: 409
Moskowitz MA Nozaki K Kraig RP Neocortical spreading drepression of c-fos protein-like immunoreactivity within trigeminal caudalis via trigeminovascular mechanisms. J Neurosci 1993; 13: 1167-1177.
Kaube H Hoskin KL Goadsby PJ Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Cephalalgia 1993; 13 Suppl 13: 41
Smith R Borchers M A novel action of sumatriptan. Cephalalgia 1993; 13 Suppl 13: 170
Skingle M Birch PJ Leighton GE Humphrey PPA Lack of antinociceptive activity of sumatriptan in rodents. Cephalalgia 1990; 10: 207-212.
Dechant KL Clissold SP Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992; 43: 776-798.
Göbel H Krapat S Ensink FB Soyka D Exteroceptive suppression of temporalis muscle activity is activated by application of sumatriptan during migraine attack but not in migraine interval. Cephalalgia 1993; 13 Suppl 13: 146
Fowler PA Lacey LF Keene ON Thomas M Effect of prophylactic migraine medications on the pharmacokinetic and pharmacodynamic profiles of sumatriptan. Cephalalgia 1991; 11: 228-229.
Scott AK Walley T Brechenridge AM Lacey LF Flower PA Lack of an interaction between propranolol and sumatriptan. Br J Clin Pharmacol 1991; 32: 581-584.
Van Hecken AM Depré M de Schepper PJ Fowler PA Lacey LF Durham JM Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. Br J Clin Pharmacol 1992; 34: 82-84
Lacey LF Fowler PA The clinical pharmacology of sumatriptan. Cephalalgia 1993; 13 Suppl 13: 156
Cutler NR Hussey EK Sramek JJ Clements BD Paulsgrove LA Busch MA, et al. Oral sumatriptan in pharmacokinetics in the migrainous state. Cephalalgia 1991; 11 Suppl 11: 222-223.
Houghton LA Fowler P Keene ON Read NW Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man. Allment Pharmacol Ther 1992; 6: 685-691.
The International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. First edition.Cephalalgia 1991; 11: 1-12
Gross M The use of sumatriptan in the treatment of migraine. Br J Clin Pract 1993; 47: 205-207.
Visser WH Ferrari MD Bayliss EM Ludlow S Pilgrim AJ Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. Cephalalgia 1992; 12: 308-313.
Couch JR Sumatriptan effective in therapy of acute migraine as demonstration by four point pain and disabling scales. Neurology 1991; 41 Suppl 1: 164
Mathew NT Dexter J Couch J Flamenbaum W Goldstein J Rapoport A, et al. Dose-ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. Arch Neurol 1992; 49: 1271-1276.
The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan: N Engl J Med 1991; 325: 316-321.
Cady RK Wendt JK Kirchner JR Sargent JD Rothrock JF Skaggs H Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265: 2831-2835.
The Sumatriptan Autoinjector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an autoinjector device. Eur Neurol 1991; 31: 323-331.
Gross MLP Kay J Turner AM Hallett K Cleal AL Hassani H on behalf of the United Kingdom Study Group. Sumatriptan in acute migraine using a novel cartridge system self-injector. Headache 1994; 34: 559-563.
Russell MB Holm-Thomsen OE Nielsen MR Cleal A Pilgrim AJ Olesen J A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. Cephalalgia 1994; 14: 291-296.
Bousser MG D'Allens H Richard A Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. J Int Med 1993; 234: 211-216.
Solbach MP Waymer RS Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol 1993; 82: 769-772.
Schoenen J Bulcke J Caekebeke J Dehaene I De Keyser J Hildebrand G, et al. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study. Cephalalgia 1994; 14: 55-63
Cady RK Dexter J Sargent JD Markley H Osterhaus JT Webster CJ Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. Neurology 1993; 43: 1363-1368.
Donoghue S Acute treatment of five migraine attacks with subcutaneous sumatriptan. Data on file, Glaxo Pharmaceuticals, 1993
O'Callaghan J Cleal AL Long-term efficacy of subcutaneous sumatriptan using a novel self-injector. Cephalalgia 1993; 13 Suppl 13; 161
Chazot G Boureau F Emile J Bertin L d'Allens H Comparison of sumatriptan with usual acute treatment of migraine. Cephalalgia 1993; 13 Suppl 13; 162
The Oral Sumatriptan Dose-Defining Study Group. Sumatriptan-an oral dose-defining study. Eur Neurol 1991; 31: 300-305.
Sargent JD Oral sumatriptan in the acute treatment of migraine; the US experience. Vth Congress of the International Headache Society, Washington USA, 1991(Glaxo Satellite Symposium):14
The Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31: 306-313.
Nappi G Sicuteri F Byrne M Roncolato M Zerbini O Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994; 241: 138-144.
Ferrari MD James MH Bates D Pilgrim AJ Ashford EA Anderson BA, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrence. Cephalalgia 1994; 14: 330-338.
Goadsby PJ Zagami AS Donnan GA Symington G Anthony M Bladin PF, et al. Oral sumatriptan in acute migraine. Lancet 1991; 338: 782-783.
The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 1992; 32: 177-184.
The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol 1991; 31: 314-322.
The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31: 332-338.
Salonen R Ashford E Dahlof C Dawson R Gilhus NE Laben V, et al. Intranasal sumatriptan for the acute treatment of migraine. J Neurol 1994; 241: 463-469.
Blakeborough P Fowler PA Ashford EA The use of sumatriptan in patients taking migraine prophylactic agents. Cephalalgia 1993; 13 Suppl 13; 163
Tansey MJB Pilgrim AJ Martin PM Long-term experience with sumatriptan in the treatment of migraine. Eur Neurol 1993; 33: 310-315.
Simmons VE Blakeborough P The safety profile of sumatriptan. Rev Contemp Pharmacother 1994; 5: 319-328.
Pilgrim AJ Long-term tolerability and safety of sumatriptan during a two-year period. Cephalalgia 1993; 13 Suppl 13: 190
Brown EG Endersby CA Smith RN Talbot JCC The safety and tolerability of sumatriptan: an overview. Eur Neurol 1991; 31: 339-344.
Pilgrim AJ Blakeborough P The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemp Pharmacother 1994; 5: 295-309
Tansey MJB Long-term safety of sumatriptan. In: Clifford Rose F, editor.New advances in headache research, vol 3. London: Smith Gordon. In press
Hillis WS MacIntyre PD Drug reactions-sumatriptan and chest pain. Lancet 1993; 341: 1564-1565.
Welch KMA Drug therapy of migraine. New Engl J Med 1993; 330: 1476-1482.
Alderton C Pilgrim AJ EGG monitoring after treatment with sumatriptan. Cephalalgia 1993; 13 Suppl 13; 166
Pilgrim AJ Stewart-Long P Fowler PA Intensive EGG surveillance in patients receiving sumatriptan after previous chest symptoms. Cephalalgia 1993; 13 Suppl 13; 16
MacIntyre PD Bhargava B Hogg KJ Gemmill JD Hillis WS Effects of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993; 87: 401-405.
Curtin T Brooks AP Roberts JA Cardiorespiratory distress after sumatriptan given by injection. Br Med J 1993; 305: 713-714.
Klingsfield P Hochreiter C Kramer H Devereux RB Niles N Kramer-Fox R, et al. Complex arhythmias in mitral regurgitation with and without mitral valve prolapse. Am J Cardiology 1985; 55: 1545-1549.
Stricker BHC Coronary vasospasm and sumatriptan. Br Med J 1992; 305: 118
Willet F Curzen N Adams J Armitage M Coronary vasospasm induced by subcutaneous sumatriptan. Br Meal J 1992; 304: 1415
Abrahamsen B Christiansen BD Angina pectoris after administration of sumatriptan. Ugeskrift for Laeger 1992; 154: 3602-3603.
Ottervanger JP Paalman HJA Boxma GL Stricker BHC Transmural myocardial infarction with sumatriptan. Lancet 1993; 341: 861-862.
Merikangas KR Comorbidity of migraine and other conditions in the general population of adults in the United States. Cephalalgia 1991; 11 Suppl 11: 108-109.
Welch KMA Levine SR Migraine-related stroke in the context of the International Headache Society classification of head pain. Arch Neurol 1990; 47: 458-462.
Luman W Gray RS Adverse reactions associated with sumatriptan. Lancet 1993; 341: 1091-1092.
Luman W Adverse reactions and sumatriptan. Lancet 1993; 341: 1662-1663.
Kloß TM Keidel M Jacob M Diener HC Intermittent hemianopsia, disorientation, parietal lobe signs, disturbances of word finding and seizures with sumatriptan. Cephalalgia. In press
Bates D Ashford E Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994; 44: 1587-1592.
Fowler PA Lacey LF Thomas M Keene ON Tanner RJN Baker NS The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291-294.
Lloyd DK Pilgrim AJ The safety of sumatriptan in asthmatic migraineurs. Cephalalgia 1993; 13: 201-204.
Henry P, d'Allens H and the French Migraine Network Bordeaux-Lyon-Grenoble. Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. Headache 1993; 33: 432-435.
Kempsford RD Lacey LF Thomas M Fowler PA The effect of alcohol on the pharmacokinetic profile of oral sumatriptan. Fund Clin Pharmacol 1991; 5: 470
Sullivan JT Preston KL Testa MP Busch M Jasinski DR Psychoactivity and abuse potential of sumatriptan. Clin Pharmacol Ther 1992; 52: 635-642.
Kaube H May A Pfaffenrath V Diener HC Sumatriptan Br Med J 1994; 308: 1573
Osborne MMJ Austin RTC Dawson KJ Lange L Is there a problem with long-term use of sumatriptan in acute migraine? Br Med J 1994; 308: 113
Tansey MJB Pilgrim AJ Lloyd K Sumatriptan in the acute treatment of migraine, J Neurol Sci 1993; 114: 109-116.
Tfelt-Hansen P Sperling B Winter PDO'B Transient additional effect of sumatriptan on ergotamine-induced constriction of peripheral arteries in man. Clin Pharmacol Ther 1992; 51: 11
Bax WA Saxena PR Sumatriptan and ischemic heart disease. Lancet 1993; 341: 1419
Bax WA Renzenbrink GJ Van Heuven-Nolsen D Thijssen EJM Bos E, et al, 5HT receptors mediating contradictions of isolated human coronary artery. Eur J Pharmacol 1993; 239: 203-210.
Saxena PR Den Boer MO Pharmacology of antimigraine drugs. J Neurol 1988; 238: 28-35
McCarthy BG Peroutka SJ Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR 43175). Headache 1989; 29: 420-422.
Rall TW Drugs affecting uterine motility. In: Gilman AG Rail TW Nies AS Taylor P, editors.Goodman and Gilman's The pharmacological basis of therapeutics, 8th Ed. New York: Pergamon Press, 1990: 933-953.
Müller-Schweinitzer E Ergot alkaloids in migraine: Is the effect via 5HT receptors? In: Olesen J Saxena PR, editors.5-Hydroxytryptamine mechanisms in primary headaches. New York: Raven Press, 297-304
Senter HJ Liebermann AN Cerebral manifestations of ergotism. Report of a case and review of the literature. Stroke 1976; 7: 88-92
Hokkanen E Waltimo O Kallanranta T Toxic effects of ergotamine used for migraine. Headache 1978; 18: 95-98
Benedict CR Angina pectoris and sudden death in the absence of atherosclerosis following ergotamine therapy for migraine. Am J Med 1979; 67: 177-178.
Ludolph AC Husstedt IW Schalke HP Grotemeyer KH Brune GG Chronic erotamine abuse: evidence of functional impairment of long ascending spinal tract. Eur Neurol 1988; 28: 311-316.
MacLean MR Smith CGS Templeton AGB Lancet 1993; 341: 1092
Lloyd DK Pilgrim AJ Simmons VE Coronary vasospasm and sumatriptan. Br Med J 1992; 305: 310-311.
Ekbom K Treatment of cluster headache in Europe, Head Q Curr Treat Res 1990; 1: 65-70
Ancalmo N Ochsner JL Peripheral ischaemia secondary to ergotamine intoxication. Arch Surg 1974; 109: 832-834.
Snell NJC Russell-Smith C Coysh HL Myocardial ischaemia in migraine sufferers taking ergotamine. Post-grad Med J 1978; 54: 37-39
Fogan L Treatment of cluster headache: a double blind comparison of oxygen vs air inhalation. Arch Neurol 1985; 42: 362-363.
Kudrow L Response of cluster headache attacks to oxygen inhalation. Headache 1982; 21: 1-4
Kittrelle JP Grouse DS Seybold ME Cluster headache: local anaesthetic abortive agents. Arch Neurol 1985; 42: 496-498.
Barre F Cocaine as an abortive agent in cluster headache. Headache 1982; 22: 69-73
Ekbom K Monstad I Prusinski A Cole JA Pilgrim AJ Noronha D The Sumatriptan Study Group: Subcutaneous sumatriptan in acute treatment of cluster headache: a dose comparison study. Acta Neurol Scand 1993; 88: 63-69
The Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Engl J Med 1991; 325: 322-326.
Gutterman DL Plachetka JR Donn K Hussey N Bhattacharyya H Leese P Evaluation of safety and pharmacological properties of single subcutaneous doses of GR43175C in healthy adult, male volunteers. Cephalalgia 1989; 9 Suppl 10: 412-413.
Krabbe A Early clinical experience with subcutaneous GR43175 in acute cluster headache attacks. Cephalalgia 1989; 9 Suppl 10: 406-407.
Ekbom K Waldenlind E Cole J, et al. Sumatriptan in chronic cluster headache: results of continuous treatment for eleven months. Cephalalgia 1992; 12: 254-256.
Ekbom K Long-term acute treatment of cluster headache attacks with sumatriptan-an interim review. Proceedings of the 6th International Headache Congress. Cephalalgia 1993; 13 Suppl 13: 36
Monstad I Preemptive oral treatment with sumatriptan during a cluster headache period. Proceedings of the 6th International Headache Congress. Cephalalgia 1993; 13 Suppl 13: 35
Wainscott S Volans G Wilkinson M Ergotamine-induced headaches. Br Med J 1974: 724
Phillips D Rawlins E Blakeborough P A diary study to monitor sumatriptan in clinical practice. Can J Neurol Sci 1993; 20 Suppl 4: 36
Diener HC Dichgans J Scholz E Geiselhart S Gerber WD Bille A Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 1989; 236: 9-14